Our preclinical GLAucoma Medication (GLAM) development program sets the ambitious aim to bring a therapeutic solution to preserve vision of patients suffering from glaucoma.
Our first-in-class therapeutic targets a mechanism of action never explored so far by the pharmaceutical industry, while offering the most effective formulation suitable for patients.
On July 2020, the jury of the 22nd i-Lab Innovation Competition of the French Ministry of Research awarded this program the National Prize.
